Human myeloid-derived suppressor cells are associated with chronic immune suppression after severe sepsis/septic shock

Annals of Surgery

Volumn 265, Issue 4, 2017, Pages 827-834

  Mathias, Brittany ^a   Delmas, Amber L ^a   Ozrazgat Baslanti, Tezcan ^a   Vanzant, Erin L ^a   Szpila, Benjamin E ^a   Mohr, Alicia M ^a   Moore, Frederick A ^a   Brakenridge, Scott C ^a   Brumback, Babette A ^a   Moldawer, Lyle L ^a   Efron, Philip A ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

compensatory anti inflammatory response syndrome; myeloid derived suppressor cell; persistent inflammation immunosuppression and catabolism syndrome; sepsis; systemic inflammatory response syndrome

Indexed keywords

ARGINASE 1; CD74 ANTIGEN; CELL SURFACE RECEPTOR; GAMMA INTERFERON; HLA DQA1 ANTIGEN; HLA DQA2 ANTIGEN; HLA DQB ANTIGEN; HLA DRB1 ANTIGEN; HLA DRB3 ANTIGEN; HLA DRB4 ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL OUTCOME; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; FLUORESCENCE SPECTROSCOPY; FUNCTIONAL STATUS; GENE EXPRESSION ASSAY; GENE EXPRESSION PROFILING; HOSPITAL DISCHARGE; HOSPITAL INFECTION; HOSPITAL MORTALITY; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELL; OBSERVATIONAL STUDY; PHENOTYPE; PROTEIN EXPRESSION; SEPSIS; SEPTIC SHOCK; TRANSCRIPTOMICS; UPREGULATION; AGED; CASE CONTROL STUDY; CHRONIC DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CROSS INFECTION; IMMUNOLOGY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SURVIVAL ANALYSIS; TRENDS;

ADULT; AGED; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; CROSS INFECTION; FEMALE; HOSPITAL MORTALITY; HUMANS; IMMUNOSUPPRESSION; MALE; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; PATIENT DISCHARGE; PROGNOSIS; RISK ASSESSMENT; SEPSIS; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 84966339558     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001783     Document Type: Article

References (37)

1. Torio CM. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011 [Agency for Healthcare Research and Quality website]. August 2013. Available at: http://www.hcup-us.ahrq.gov/reports/statbriefs/sb160.pdf. Accessed February 17, 2016
2. Sands KE, Bates DW, Lanken PN, et a.l. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA. 1997; 278: 234-240
3. Rimmele T, Payen D, Cantaluppi V, et a.l. Immune cell phenotype and function in sepsis. Shock. 2016; 45: 282-291
4. Nelson JE, Cox CE, Hope AA, et a.l. Chronic critical illness. Am J Respir Crit Care Med. 2010; 182: 446-454
5. Gentile LF, Cuenca AG, Efron PA, et a.l. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J Trauma Acute Care Surg. 2012; 72: 1491-1501
6. Cuenca AG, Delano MJ, Kelly-Scumpia KM, et al A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med. 2011; 17: 281-292
7. Vanzant EL, Lopez CM, Ozrazgat-Baslanti T, et a.l. Persistent inflammation, immunosuppression, and catabolism syndrome after severe blunt trauma. J Trauma Acute Care Surg. 2014; 76: 21-30
8. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med. 2014; 371: 380-383
9. Youn JI, Gabrilovich DI. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010; 40: 2969-2975
10. Rodrigues JC, Gonzalez GC, Zhang L, et a.l. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010; 12: 351-365
11. Filipazzi P, Valenti R, Huber V, et a.l. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007; 25: 2546-2553
12. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9: 162-174
13. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015; 125: 3356-3364
14. Cuenca AG, Moldawer LL. Myeloid-derived suppressor cells in sepsis: friend or foe? Intensive Care Med. 2012; 38: 928-930
15. Delano MJ, Scumpia PO, Weinstein JS, et a.l. MyD88-dependent expansion of an immature GR-1(-)CD11b(-) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med. 2007; 204: 1463-1474
16. Darcy CJ, Minigo G, Piera KA, et a.l. Neutrophils with myeloid derived suppressor function deplete arginine and constrain T cell function in septic shock patients. Crit Care. 2014; 18: R163
17. Janols H, Bergenfelz C, Allaoui R, et al A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. J Leukoc Biol. 2014; 96: 685-693
18. Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997; 25: 1789-1795
19. Movahedi K, Guilliams M, Van den Bossche J, et a.l. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood. 2008; 111: 4233-4244
20. Damuzzo V, Pinton L, Desantis G, et a.l. Complexity and challenges in defining myeloid-derived suppressor cells. Cytometry B Clin Cytom. 2015; 88: 77-91
21. Scumpia PO, Delano MJ, Kelly-Scumpia KM, et a.l. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood. 2007; 110: 3673-3681
22. Zhu X, Pribis JP, Rodriguez PC, et a.l. The central role of arginine catabolism in T-cell dysfunction and increased susceptibility to infection after physical injury. Ann Surg. 2014; 259: 171-178
23. Clermont G, Angus DC, Kalassian KG, et a.l. Reassessing the value of shortterm mortality in sepsis: comparing conventional approaches to modeling. Crit Care Med. 2003; 31: 2627-2633
24. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis. 2002; 34: 1084-1093
25. Starr ME, Ueda J, Yamamoto S, et a.l. The effects of aging on pulmonary oxidative damage, protein nitration, and extracellular superoxide dismutase down-regulation during systemic inflammation. Free Radic Biol Med. 2011; 50: 371-380
26. Dombrovskiy VY, Martin AA, Sunderram J, et a.l. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007; 35: 1244-1250
27. Xiao W, Mindrinos MN, Seok J, et al A genomic storm in critically injured humans. J Exp Med. 2011; 208: 2581-2590
28. Probst C, Pape HC, Hildebrand F, et a.l. 30 years of polytrauma care: an analysis of the change in strategies and results of 4849 cases treated at a single institution. Injury. 2009; 40: 77-83
29. Probst C, Zelle BA, Sittaro NA, et a.l. Late death after multiple severe trauma: when does it occur and what are the causes? J Trauma. 2009; 66: 1212-1217
30. Sasser SM, Varghese M, Joshipura M, et a.l. Preventing death and disability through the timely provision of prehospital trauma care. Bull World Health Organ. 2006; 84: 507
31. Chang DW, Tseng CH, Shapiro MF. Rehospitalizations following sepsis: common and costly. Crit Care Med. 2015; 43: 2085-2093
32. Bueno V, Sant'Anna OA, Lord JM. Ageing and myeloid-derived suppressor cells: possible involvement in immunosenescence and age-related disease. Age (Dordr). 2014; 36: 9729
33. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013; 13: 739-752
34. Nacionales DC, Szpila B, Ungaro R, et al A detailed characterization of the dysfunctional immunity and abnormal myelopoiesis induced by severe shock and trauma in the aged. J Immunol. 2015; 195: 2396-2407
35. Nacionales DC, Gentile LF, Vanzant E, et a.l. Aged mice are unable to mount an effective myeloid response to sepsis. J Immunol. 2014; 192: 612-622
36. Meirow Y, Kanterman J, Baniyash M. Paving the road to tumor development and spreading: myeloid-derived suppressor cells are ruling the fate. Front Immunol. 2015; 6: 523
37. Manjili MH. Phenotypic plasticity of MDSC in cancers. Immunol Invest. 2012; 41: 711-721